LEXINGTON, Mass., Nov. 28, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development ofnext-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at Citi's 2018 Global Healthcare
About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: 781-761-4904 ext. 218 firstname.lastname@example.org
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.email@example.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-participate-at-citis-2018-global-healthcare-conference-300756510.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!